US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Alvotech - Ordinary Shares (NQ:ALVO)

6.110 +0.660 (+12.11%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
News headline image
ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 ↗
Alvotech just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Alvotech's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
From Alvotech
Via GlobeNewswire
News headline image
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
News headline image
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
From Alvotech
Via GlobeNewswire
News headline image
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
Alvotech Announces Increase in Number of Own Shares
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Earnings Scheduled For March 20, 2024 ↗
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million. 
Via Benzinga
News headline image
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Appoints Interim Chief Quality Officer
From Alvotech
Via GlobeNewswire
News headline image
TEVA Stock Pops 4% as Teva Receives FDA Approval ↗
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar. 
Via InvestorPlace
News headline image
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today? ↗
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more. 
Via Benzinga
News headline image
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
News headline image
American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >